ReviewMolecular and cellular biochemistry2022
The role of endoglin and its soluble form in pathogenesis of preeclampsia.
Review in Molecular and cellular biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Association between blood lipid levels and preeclampsia: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Advances in pathogenesis of preeclampsia.Archives of gynecology and obstetrics · 2024Pooled it
- Artificial Intelligence for the Prediction of Preeclampsia: Current Evidence, Comparison with Conventional Screening Models, and Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
- Cardiac Biomarkers and Pregnancy-Associated Cardiovascular Disease.Current cardiology reports · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Longitudinal patterns of urinary biomarkers of placental and renal function in pregnancy and associations with early pregnancy exposure to phthalates and replacements.Reproductive toxicology (Elmsford, N.Y.) · 2026Article
- Identifying biomarkers of the serum proteins and metabolites associated with severe preeclampsia.BMC pregnancy and childbirth · 2026Article
- Placental Steroid Hormones in Preeclampsia: Multilayered Regulation of Endocrine Pathogenesis.Endocrine reviews · 2026Review
- Integrative bioinformatics analysis identifies placental senescence-associated signatures in early-onset preeclampsia.Frontiers in endocrinology · 2026Article
- Article
- The Role of microRNA-210 in the Pathogenesis and Diagnosis of Preeclampsia-A Systematic Review.Journal of clinical medicine · 2025Review
- The emerging role of human transmembrane RGD-based counter-receptors of integrins in health and disease.Cellular & molecular biology letters · 2025Review
- The human placenta and its role in reproductive outcomes revisited.Physiological reviews · 2025Review
- Molecular profiles of the great obstetrical syndromes reveal common features and dynamic changes in early pregnancy.Communications medicine · 2025Article
- Factors influencing health promotion behavior on puerperal sepsis among postpartum mothers.BMC pregnancy and childbirth · 2025Article
- Universal First-Trimester Screening Biomarkers for Diagnosis of Preeclampsia and Placenta Accreta Spectrum.Biomolecules · 2025Article
- Comparison of Characteristics Between Early-Onset and Late-Onset Severe Preeclampsia: A Retrospective Cohort Study from a Tertiary Hospital in China.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Preeclampsia prediction and diagnosis: a comprehensive historical review from clinical insights to omics perspectives.Frontiers in medicine · 2025Review
- Prediction of late-onset preeclampsia using plasma proteomics: a longitudinal multi-cohort study.Scientific reports · 2024Article
- Sensing Platform Based on Gold Nanoclusters and Nanoporous Anodic Alumina for Preeclampsia Detection.Biosensors · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia remains till today a leading cause of maternal and fetal morbidity and mortality. Pathophysiology of the disease is not yet fully elucidated, though it is evident that it revolves around placenta. Cellular ischemia in the preeclamptic placenta creates an imbalance between angiogenic and anti-angiogenic factors in maternal circulation. Endoglin, a transmembrane co-receptor of transforming growth factor β (TGF-β) demonstrating angiogenic effects, is involved in a variety of angiogenesis-dependent diseases with endothelial dysfunction, including preeclampsia. Endoglin expression is up-regulated in preeclamptic placentas, through mechanisms mainly induced by hypoxia, oxidative stress and oxysterol-mediated activation of liver X receptors. Overexpression of endoglin results in an increase of its soluble form in maternal circulation. Soluble endoglin represents the extracellular domain of membrane endoglin, cleaved by the action of metalloproteinases, predominantly matrix metalloproteinase-14. Released in circulation, soluble endoglin interferes in TGF-β1 and activin receptor-like kinase 1 signaling pathways and inhibits endothelial nitric oxide synthase activation, consequently deranging angiogenesis and promoting vasoconstriction. Due to these properties, soluble endoglin actively contributes to the impaired placentation observed in preeclampsia, as well as to the pathogenesis and manifestation of its clinical signs and symptoms, especially hypertension and proteinuria. The significant role of endoglin and soluble endoglin in pathophysiology of preeclampsia could have prognostic, diagnostic and therapeutic perspectives. Further research is essential to extensively explore the potential use of these molecules in the management of preeclampsia in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.